MDWD MediWound

MediWound to Present at Upcoming Investor Conferences

MediWound to Present at Upcoming Investor Conferences

MediWound to Present at Upcoming Investor Conferences

YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences:

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Date: Thursday, February 26, 2026

Time: 10:40 a.m. ET

Location: Virtual

Webcast:

TD Cowen 46th Annual Health Care Conference

Date: Monday, March 2, 2026

Time: 1:10 p.m. ET

Location: Boston Marriott Copley Place, Boston, MA

Webcast:

A live webcast and replay of each presentation will be accessible through the section of the Investor Relations area of MediWound’s website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.

For more information, visit and follow us on and .



MediWound Contacts:        







Hani Luxenburg        

Chief Financial Officer

MediWound Ltd.



Daniel Ferry

Managing Director

LifeSci Advisors, LLC







EN
17/02/2026

Underlying

MDWDMediWound

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediWound

 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued...

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARD...

33m 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Files Annual Report on Form 20-F

MediWound Files Annual Report on Form 20-F MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on March 5, 2026. The annual report can be accessed on the SEC’s website at , as well as via the Company’s investor relations website at . The Company will provide a hard copy of its annual report o...

March 5, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results EscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in cash at year-end; 2026–2028 revenue guidance reaffirmed Conference Call Today, March 5, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for...

March 5, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Report Fourth Quarter and Full Year 2025 Financial Result...

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026. Following the release, MediWound’s management will host a conference ca...

February 19, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Present at Upcoming Investor Conferences

MediWound to Present at Upcoming Investor Conferences MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Time: 10:40 a.m. ET Location: Virtual Webcast: TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Time: 1:10 p.m. ET ...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch